CN110167938B - 作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途 - Google Patents

作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途 Download PDF

Info

Publication number
CN110167938B
CN110167938B CN201880006261.0A CN201880006261A CN110167938B CN 110167938 B CN110167938 B CN 110167938B CN 201880006261 A CN201880006261 A CN 201880006261A CN 110167938 B CN110167938 B CN 110167938B
Authority
CN
China
Prior art keywords
acetonitrile
cyclohexyl
imidazo
pyridin
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880006261.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110167938A (zh
Inventor
J·拉森
M·拉森
L·K·拉斯穆森
A·里岑
T·M·杜斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akileon Ltd
Original Assignee
Leo Pharma AS
Akileon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS, Akileon Ltd filed Critical Leo Pharma AS
Publication of CN110167938A publication Critical patent/CN110167938A/zh
Application granted granted Critical
Publication of CN110167938B publication Critical patent/CN110167938B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880006261.0A 2017-01-11 2018-01-10 作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途 Active CN110167938B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17151020.9 2017-01-11
EP17151020 2017-01-11
PCT/EP2018/050548 WO2018130563A1 (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
CN110167938A CN110167938A (zh) 2019-08-23
CN110167938B true CN110167938B (zh) 2024-06-14

Family

ID=57777557

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880006261.0A Active CN110167938B (zh) 2017-01-11 2018-01-10 作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途

Country Status (26)

Country Link
US (1) US10703751B2 (enExample)
EP (1) EP3568396B1 (enExample)
JP (1) JP7009504B2 (enExample)
KR (1) KR102548543B1 (enExample)
CN (1) CN110167938B (enExample)
AU (1) AU2018208516B2 (enExample)
CA (1) CA3045567A1 (enExample)
CY (1) CY1123864T1 (enExample)
DK (1) DK3568396T3 (enExample)
ES (1) ES2846741T3 (enExample)
HR (1) HRP20210095T1 (enExample)
HU (1) HUE052720T2 (enExample)
IL (1) IL267829B (enExample)
LT (1) LT3568396T (enExample)
MX (1) MX389378B (enExample)
MY (1) MY195576A (enExample)
NZ (1) NZ754922A (enExample)
PL (1) PL3568396T3 (enExample)
PT (1) PT3568396T (enExample)
RS (1) RS61317B1 (enExample)
RU (1) RU2019125177A (enExample)
SI (1) SI3568396T1 (enExample)
TW (1) TWI760419B (enExample)
UA (1) UA123972C2 (enExample)
WO (1) WO2018130563A1 (enExample)
ZA (1) ZA201904190B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
ES2922379T3 (es) 2016-12-16 2022-09-14 Janssen Pharmaceutica Nv Compuestos de imidazo[4,5,D]pirrolo[2,3,B]piridina como inhibidores de Janus quinasas
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020007698A1 (en) * 2018-07-06 2020-01-09 Leo Pharma A/S Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
WO2021040502A1 (ko) * 2019-08-30 2021-03-04 주식회사 티에스디라이프사이언스 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN119569971B (zh) * 2025-02-07 2025-05-27 吉林大学 一种用于蛋白质磷酸化和棕榈酰化修饰同时筛选的Janus材料的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955824A (zh) * 2012-11-20 2015-09-30 基因泰克公司 作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101981033B (zh) * 2008-02-06 2015-02-04 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
KR20140015162A (ko) 2010-01-12 2014-02-06 에프. 호프만-라 로슈 아게 트라이사이클릭 헤테로사이클릭 화합물, 조성물 및 이의 사용 방법
CN103168032A (zh) * 2010-08-05 2013-06-19 安美基公司 抑制间变性淋巴瘤激酶的苯并咪唑和氮杂苯并咪唑化合物
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
UY34615A (es) 2012-02-10 2013-09-30 Galapagos Nv Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
CN104098563A (zh) 2013-04-02 2014-10-15 山东亨利医药科技有限责任公司 Jnk抑制剂化合物
CR20160553A (es) 2014-04-30 2017-04-25 Incyte Corp Procesos para preparar un inhibidor de jak1 y nuevas formas de este
MX390005B (es) 2016-10-03 2025-03-20 Hangzhou Highlightll Pharmaceutical Co Ltd Inhibidores selectivos de jak1 novedosos y usos de los mismos.
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955824A (zh) * 2012-11-20 2015-09-30 基因泰克公司 作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物

Also Published As

Publication number Publication date
US10703751B2 (en) 2020-07-07
US20190367512A1 (en) 2019-12-05
ES2846741T3 (es) 2021-07-29
RU2019125177A (ru) 2021-02-15
ZA201904190B (en) 2020-10-28
KR102548543B1 (ko) 2023-06-29
TW201829407A (zh) 2018-08-16
PL3568396T3 (pl) 2021-05-31
JP7009504B2 (ja) 2022-01-25
HRP20210095T1 (hr) 2021-03-05
MX2019008331A (es) 2020-01-14
JP2020504186A (ja) 2020-02-06
RU2019125177A3 (enExample) 2021-05-11
CN110167938A (zh) 2019-08-23
PT3568396T (pt) 2021-02-09
AU2018208516B2 (en) 2021-07-08
TWI760419B (zh) 2022-04-11
NZ754922A (en) 2025-11-28
RS61317B1 (sr) 2021-02-26
CA3045567A1 (en) 2018-07-19
MX389378B (es) 2025-03-20
EP3568396A1 (en) 2019-11-20
SI3568396T1 (sl) 2021-04-30
IL267829A (en) 2019-09-26
BR112019014191A2 (pt) 2020-02-11
DK3568396T3 (da) 2021-01-18
IL267829B (en) 2022-02-01
EP3568396B1 (en) 2020-11-11
WO2018130563A1 (en) 2018-07-19
MY195576A (en) 2023-02-02
HUE052720T2 (hu) 2021-05-28
CY1123864T1 (el) 2022-05-27
AU2018208516A1 (en) 2019-07-11
UA123972C2 (uk) 2021-06-30
KR20190103231A (ko) 2019-09-04
LT3568396T (lt) 2021-02-10

Similar Documents

Publication Publication Date Title
CN110167938B (zh) 作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途
EP3190889B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP2964223B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CA2790070C (en) Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
CN106905322B (zh) 吡咯嘧啶五元氮杂环衍生物及其应用
CN105263934B (zh) 作为bet抑制剂的吡唑并‑吡咯烷‑4‑酮衍生物及其在治疗疾病中的用途
CA2818545A1 (en) Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CN105452239A (zh) 作为jak抑制剂的联吡唑衍生物
RU2764980C2 (ru) Бициклические амины в качестве новых ингибиторов jak-киназы
CN112898269A (zh) 化合物的结晶形式
KR20240055788A (ko) 신규한 ras 억제제
WO2019011228A1 (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
RU2761626C2 (ru) ПРОИЗВОДНЫЕ 5-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-5-АЗАСПИРО[2.5]ОКТАН-8-КАРБОНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ НОВЫХ ИНГИБИТОРОВ JAK-КИНАЗЫ
CN105102435A (zh) 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
HK40013317B (zh) 作为janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途
CA3222404A1 (en) Heterocyclic jak inhibitor
HK40013317A (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
BR112019014191B1 (pt) Composto e composição farmacêutica
WO2025151602A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
WO2025087267A1 (zh) 一种含有噻唑基的哌啶并嘧啶类衍生物、其制备方法及其医药上的应用
HK40053244A (en) Pyridazinone derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013317

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20221109

Address after: Helsingborg

Applicant after: Akileon Ltd.

Address before: Rupp, Denmark

Applicant before: LEO PHARMA A/S

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant